Transcatheter Tricuspid Valve Repair

MASTER TR TECHNOLOGY WITH LEADING CLINICAL OUTCOMES¹





Information contained herein for **DISTRIBUTION In Australia and New Zealand ONLY.**

FIRST AND FOREMOST.

EVERY TIME.

OVER TIME.

DESIGNED FOR THE RIGHT HEART WITH LEADING CLINICAL OUTCOMES¹

IMPLANT SUCCESS RATE

100% implant success rate in the TRILUMINATE[™] Clinical Trial

SAFETY

- 0% mortality at discharge
- 93% freedom from major adverse events at 1 year

EFFICACY

Proven outcomes sustained at 1 year:

- 87% of patients with reduction of TR
- 70% of patients with moderate or less TR

QUALITY OF LIFE

Proven outcomes sustained

at 1 year:

- 83% of patients in NYHA I/II
- 20-point increase in KCCQ-OS#

DURABILITY

Proven outcomes sustained at 1 year:

- 11% increase in 6MWD
- **40%** reduction in hospitalizations

SURVIVAL

- 0% mortality at 30 days
- 93% survival at 1 year

TREATMENT OF A BROAD **RANGE OF TRICUSPID VALVE ANATOMIES*** DESIGNED FOR STABILITY DURING STEERING AND POSITIONING

MULTIAXIS STEERING

Designed to deliver catheter movement across all lines of coaptation while maintaining perpendicularity to the valve plane

DELIVERY SYSTEM CURVES

Anatomically designed for the height you need for direct access to the valve

[#]Large is defined as > 20-point difference in KCCQ score.

Information contained herein for DISTRIBUTION in Australia and New Zealand ONLY.

DESIGNED FOR PRECISE AND CONTROLLED IMPLANTATION

CONTROLLED STEERING, POSITIONING AND DEPLOYMENT

HIGH TORQUE RESPONSE²

During steering and positioning

STABLE CLIP ARM ORIENTATION ²

When crossing the valve and grasping leaflets

STRAIGHT TRAJECTORY²

Into the right ventricle

REDUCTION OF TR³ EFFECTIVE LEAFLET CAPTURE AND DISTRIBUTION OF

RETENTION FORCES

TWO IMPLANT SIZES

For patient-specific therapy options







XT provides 44% more coaptation surface area than the TriClip™ NT

Information contained herein for **DISTRIBUTION in Australia and New Zealand ONLY.**

WIDE GRASPING OPENING

Designed to optimise the amount of leaflet tissue insertion while minimizing leaflet tension



GRIPPERS DESIGNED TO DISTRIBUTE RETENTION FORCE

To grasp the leaflet with confidence



THE TRICLIP[™] DELIVERY SYSTEM

TECHNOLOGY WITH LEADING CLINICAL OUTCOMES¹, WITH A DELIVERY SYSTEM DESIGNED FOR THE TRICUSPID VALVE

F/E KNOB

Flexes and extends delivery catheter to steer down to the valve plane

S/L KNOB

Enables movement in septal or lateral directions

TRICLIP STEERABLE GUIDE CATHETER -

Designed for the right side

- Provides adequate height over the valve
- Enables physicians to maintain coaxial position during steering and positioning
- Allows sweeping away from the septum to optimize delivery catheter perpendicularity to the tricuspid valve

+/- KNOB

Straightens and curves guide for height adjustment above the valve

Information contained herein for **DISTRIBUTION In Australia and New Zealand ONLY.**

TRICLIP[™] DELIVERY SYSTEM

- Designed to provide stability and precision during steering and positioning
- Multiaxis steering designed to enable navigation across all lines of coaptation



DISTAL CURVE

Designed for optimized access to the tricuspid valve

6MWD	six-minute walk distance
F/E	flex/extend
КССQ	Kansas City Cardiomyopathy Questionnaire
KCCQ-OS	Kansas City Cardiomyopathy Questionnaire Overall Summa
NYHA	New York Heart Association
S/L	septal/lateral
TR	tricuspid regurgitation

Information contained herein for **DISTRIBUTION In Australia and New Zealand ONLY.**

rv

 Lurz P, Stephan von Bardeleben R, Weber M, Sitges M, Sorajja P, Hausleiter J, Denti P, Trochu JN, Nabauer M, Tang GHL, Biaggi P, Ying SW, Trusty PM, Dahou A, Hahn RT, Nickenig G, Investigators T. Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation. J Am Coll Cardiol 2021;77(3):229-239.

2. Data on file at Abbott

3. Nickenig et al, (2019). Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet 2019; 394: 2002–11. doi: https://doi.org/10.1016/S0140-6736(19)32600-5 CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott

Abbott Medical Australia Pty Ltd: 299 Lane Cove Road, Macquarie Park, NSW 2113 Tel: 1800 839 259

Abbott Medical New Zealand Ltd, Ground Floor, Bldg D, 4 Pacific Rise, Mount Wellington, Auckland 1060 Ph: 0800 656 233 W: www.aus.abbott © 2021 Abbott. All Rights Reserved.

[™] Indicates a trademark of the Abbott group of companies.

© 2021 Abbott. All Rights Reserved.

MAT-2102890v1.0 | Item approved for ANZ use only.

